These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8738200)

  • 21. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.
    Flynn TN; Kelsey SM; Hazel DL; Guest JF
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):543-50. PubMed ID: 10662479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
    Trenschel R; Peceny R; Runde V; Elmaagacli A; Dermoumi H; Heintschel von Heinegg E; Müller KD; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2000 Nov; 26(9):993-7. PubMed ID: 11100279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
    Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
    Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
    Colombo GL; Morlotti L; Serra G
    Recenti Prog Med; 2005 Sep; 96(9):416-23. PubMed ID: 16229321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I
    Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
    Dranitsaris G; Khoury H
    Support Care Cancer; 2011 Nov; 19(11):1807-13. PubMed ID: 20972589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Fluconazole Prophylaxis Regimen and the Regimes Chosen by the Patient’s Risk of Fungal Infection in Reducing the Infection Rate after Bone Marrow Transplantation.
    Pourghasemian M; Mehdizadeh M; Hajfathali A; Habibzadeh A; Hosseini MH
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1543-1546. PubMed ID: 29936729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
    O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
    Value Health; 2009; 12(5):666-73. PubMed ID: 19508661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
    de la Cámara R; Jarque I; Sanz MA; Grau S; Casado MA; Sabater FJ; Carreras E
    Bone Marrow Transplant; 2010 May; 45(5):925-32. PubMed ID: 19802030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis.
    Wang Y; Xing Y; Chen L; Meng T; Li Y; Xie J; Chen L; Dong Y; Dong W
    Int J Hematol; 2018 Feb; 107(2):235-243. PubMed ID: 29027638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifungal prophylaxis in bone marrow transplant.
    Lam HH; Althaus BL
    Ann Pharmacother; 1995 Sep; 29(9):921-4. PubMed ID: 8547742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis of fungal infections.
    Schuler US; Haag C
    Mycoses; 1997; 40 Suppl 2():41-4. PubMed ID: 9476504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
    Papadopoulos G; Hunt S; Prasad M
    J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole.
    Oliveira JS; Kerbauy FR; Colombo AL; Bahia DM; Pinheiro GS; Silva MR; Ribeiro MS; Raineri G; Kerbauy J
    Braz J Med Biol Res; 2002 Jul; 35(7):789-98. PubMed ID: 12131918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nystatin prophylaxis and treatment in severely immunodepressed patients.
    Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002033. PubMed ID: 25188770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
    Goa KL; Barradell LB
    Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.
    Imataki O; Kubota Y; Ohnishi H; Kitanaka A; Ishida T; Tanaka T
    Support Care Cancer; 2011 Oct; 19(10):1657-65. PubMed ID: 20830490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.